Dual-targeted therapy with trastuzumab and lapatinib in treatment-refractory, KRAS codon 12/13 wild-type, HER2-positive metastatic colorectal cancer (HERACLES): a proof-of-concept, multicentre, open-label, phase 2 trial

The Lancet Oncology

Volumn 17, Issue 6, 2016, Pages 738-746

  Sartore Bianchi, Andrea ^a   Trusolino, Livio ^b,g   Martino, Cosimo ^b   Bencardino, Katia ^a   Lonardi, Sara ^c   Bergamo, Francesca ^c   Zagonel, Vittorina ^c   Leone, Francesco ^b,g   Depetris, Ilaria ^g   Martinelli, Erika ^d   Troiani, Teresa ^d   Ciardiello, Fortunato ^d   Racca, Patrizia ^e   Bertotti, Andrea ^b,g   Siravegna, Giulia ^b,g   Torri, Valter ^f   Amatu, Alessio ^a   Ghezzi, Silvia ^a   Marrapese, Giovanna ^a   Palmeri, Laura ^a   Valtorta, Emanuele ^a   Cassingena, Andrea ^a   Lauricella, Calogero ^a   Vanzulli, Angelo ^a   Regge, Daniele ^b,g   Veronese, Silvio ^a   Comoglio, Paolo M ^b,g   Bardelli, Alberto ^b,g   Marsoni, Silvia ^b   Siena, Salvatore ^a,h   more..

^a OSPEDALE NIGUARDA CA GRANDA   (Italy)

^b CANDIOLO CANCER INSTITUTE   (Italy)

^c VENETO INSTITUTE OF ONCOLOGY IOV IRCCS   (Italy)

^d SECOND UNIVERSITY OF NAPLES   (Italy)

^e CITTÀ DELLA SALUTE E DELLA SCIENZA HOSPITAL   (Italy)

^f MARIO NEGRI INSTITUTE FOR PHARMACOLOGICAL RESEARCH   (Italy)

^g UNIVERSITY OF TURIN   (Italy)

^h UNIVERSITY OF MILAN   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR 2; LAPATINIB; TRASTUZUMAB; ANTINEOPLASTIC AGENT; CODON; KRAS PROTEIN, HUMAN; PROTEIN P21; QUINAZOLINE DERIVATIVE; TUMOR MARKER;

ABDOMINAL PAIN; ADULT; AGED; ANOREXIA; ARTICLE; CANCER DIAGNOSIS; CODON; CONJUNCTIVITIS; CONTROLLED STUDY; DERMATITIS; DIARRHEA; DOSE RESPONSE; DRY SKIN; ERYTHEMA; EXON; FATIGUE; FEMALE; FLUORESCENCE IN SITU HYBRIDIZATION; FOLLICULITIS; HAND FOOT SYNDROME; HUMAN; HYPERBILIRUBINEMIA; IMMUNOHISTOCHEMISTRY; INTENTION TO TREAT ANALYSIS; LOADING DRUG DOSE; MAJOR CLINICAL STUDY; MALE; METASTATIC COLORECTAL CANCER; MULTICENTER STUDY; MULTIPLE CYCLE TREATMENT; NAIL DISEASE; NAUSEA; ONCOGENE K RAS; PARONYCHIA; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; PRURITUS; RASH; TREATMENT OUTCOME; VOMITING; WILD TYPE; ANTAGONISTS AND INHIBITORS; CANCER STAGING; CLINICAL TRIAL; COLORECTAL NEOPLASMS; DRUG EFFECTS; DRUG RESISTANCE; ENZYME IMMUNOASSAY; FOLLOW UP; GENETICS; METABOLISM; METASTASIS; MIDDLE AGED; MOLECULARLY TARGETED THERAPY; PATHOLOGY; PROGNOSIS; SALVAGE THERAPY; SURVIVAL RATE; TUMOR RECURRENCE;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BIOMARKERS, TUMOR; CODON; COLORECTAL NEOPLASMS; DRUG RESISTANCE, NEOPLASM; FEMALE; FOLLOW-UP STUDIES; HUMANS; IMMUNOENZYME TECHNIQUES; MALE; MIDDLE AGED; MOLECULAR TARGETED THERAPY; NEOPLASM METASTASIS; NEOPLASM RECURRENCE, LOCAL; NEOPLASM STAGING; PROGNOSIS; PROTO-ONCOGENE PROTEINS P21(RAS); QUINAZOLINES; RECEPTOR, ERBB-2; SALVAGE THERAPY; SURVIVAL RATE; TRASTUZUMAB;

EID: 84963976837     PISSN: 14702045     EISSN: 14745488     Source Type: Journal    
DOI: 10.1016/S1470-2045(16)00150-9     Document Type: Article

References (33)

1. 1 Vogelstein, B, Papadopoulos, N, Velculescu, VE, Zhou, S, Diaz, LA, Kinzler, KW, Cancer genome landscapes. Science 339 (2013), 1546–1558.
2. 2 Network, CGA, Comprehensive molecular characterization of human colon and rectal cancer. Nature 487 (2012), 330–337.
3. 3 Bertotti, A, Papp, E, Jones, S, et al. The genomic landscape of response to EGFR blockade in colorectal cancer. Nature 526 (2015), 263–267.
4. 4 Fakih, MG, Metastatic colorectal cancer: current state and future directions. J Clin Oncol 33 (2015), 1809–1824.
5. 5 Moroni, M, Veronese, S, Benvenuti, S, et al. Gene copy number for epidermal growth factor receptor (EGFR) and clinical response to antiEGFR treatment in colorectal cancer: a cohort study. Lancet Oncol 6 (2005), 279–286.
6. 6 Siena, S, Sartore-Bianchi, A, Di Nicolantonio, F, Balfour, J, Bardelli, A, Biomarkers predicting clinical outcome of epidermal growth factor receptor-targeted therapy in metastatic colorectal cancer. J Natl Cancer Inst 101 (2009), 1308–1324.
7. 7 Misale, S, Di Nicolantonio, F, Sartore-Bianchi, A, Siena, S, Bardelli, A, Resistance to anti-EGFR therapy in colorectal cancer: from heterogeneity to convergent evolution. Cancer Discov 4 (2014), 1269–1280.
8. 8 Bertotti, A, Migliardi, G, Galimi, F, et al. A molecularly annotated platform of patient-derived xenografts (“xenopatients”) identifies HER2 as an effective therapeutic target in cetuximab-resistant colorectal cancer. Cancer Discov 1 (2011), 508–523.
9. 9 Leto, SM, Sassi, F, Catalano, I, et al. Sustained inhibition of HER3 and EGFR is necessary to induce regression of HER2-amplified gastrointestinal carcinomas. Clin Cancer Res 21 (2015), 5519–5531.
10. 10 Blackwell, KL, Burstein, HJ, Storniolo, AM, et al. Randomized study of Lapatinib alone or in combination with trastuzumab in women with ErbB2-positive, trastuzumab-refractory metastatic breast cancer. J Clin Oncol 28 (2010), 1124–1130.
11. 11 Valtorta, E, Martino, C, Sartore-Bianchi, A, et al. Assessment of a HER2 scoring system for colorectal cancer: results from a validation study. Mod Pathol 28 (2015), 1481–1491.
12. 12 A'Hern, RP, Sample size tables for exact single-stage phase II designs. Stat Med 20 (2001), 859–866.
13. 13 Hanley, JA, McNeil, BJ, The meaning and use of the area under a receiver operating characteristic (ROC) curve. Radiology 143 (1982), 29–36.
14. 14 Harrell, FE, Califf, RM, Pryor, DB, Lee, KL, Rosati, RA, Evaluating the yield of medical tests. JAMA 247 (1982), 2543–2546.
15. 15 Strobl, C, Malley, J, Tutz, G, An introduction to recursive partitioning: rationale, application, and characteristics of classification and regression trees, bagging, and random forests. Psychol Methods 14 (2009), 323–348.
16. 16 Sartore-Bianchi, A, Ardini, E, Bosotti, R, et al. Sensitivity to entrectinib associated with a novel LMNA-NTRK1 gene fusion in metastatic colorectal cancer. J Natl Cancer Inst, 108, 2016, djv306.
17. 17 Amatu, A, Somaschini, A, Cerea, G, et al. Novel CAD-ALK gene rearrangement is drugable by entrectinib in colorectal cancer. Br J Cancer 113 (2015), 1730–1734.
18. 18 Clark, JW, Niedzwiecki, D, Hollis, D, Mayer, R, Phase II trial of 5-fluororuacil (5-FU), leucovorin (LV), oxaliplatin (Ox), and trastuzumab (T) for patients with metastatic colorectal cancer (CRC) refractory to initial therapy. Proc Am Soc Clin Oncol, 21, 2003, 3584 (abstr).
19. 19 Ramanathan, RK, Hwang, JJ, Zamboni, WC, et al. Low overexpression of HER-2/neu in advanced colorectal cancer limits the usefulness of trastuzumab (Herceptin) and irinotecan as therapy. A phase II trial. Cancer Invest 22 (2004), 858–865.
20. 20 Sorscher, SM, Marked response to single agent trastuzumab in a patient with metastatic HER-2 gene amplified rectal cancer. Cancer Invest 29 (2011), 456–459.
21. 21 Bensch, F, van Rooijen, JM, Schröder, CP, Reyners, AK, A 21-year-old patient with a HER2-positive colorectal cancer. Gastroenterology 148 (2015), 20–21.
22. 22 Grothey, A, Van Cutsem, E, Sobrero, A, et al. Regorafenib monotherapy for previously treated metastatic colorectal cancer (CORRECT): an international, multicentre, randomised, placebo-controlled, phase 3 trial. Lancet 381 (2013), 303–312.
23. 23 Li, J, Qin, S, Xu, R, et al., CONCUR Investigators. Regorafenib plus best supportive care versus placebo plus best supportive care in Asian patients with previously treated metastatic colorectal cancer (CONCUR): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncol 16 (2015), 619–629.
24. 24 Mayer, RJ, Van Cutsem, E, Falcone, A, et al. Randomized trial of TAS-102 for refractory metastatic colorectal cancer. N Engl J Med 372 (2015), 1909–1919.
25. 25 Price, TJ, Peeters, M, Kim, TW, et al. Panitumumab versus cetuximab in patients with chemotherapy-refractory wild-type KRAS exon 2 metastatic colorectal cancer (ASPECCT): a randomised, multicentre, open-label, non-inferiority phase 3 study. Lancet Oncol 15 (2014), 569–579.
26. 26 Yonesaka, K, Zejnullahu, K, Okamoto, I, et al. Activation of ERBB2 signaling causes resistance to the EGFR-directed therapeutic antibody cetuximab. Sci Transl Med, 3, 2011, 99ra86.
27. 27 Martin, V, Landi, L, Molinari, F, et al. HER2 gene copy number status may influence clinical efficacy to anti-EGFR monoclonal antibodies in metastatic colorectal cancer patients. Br J Cancer 108 (2013), 668–675.
28. 28 Missiaglia, E, Jacobs, B, D'Ario, G, et al. Distal and proximal colon cancers differ in terms of molecular, pathological, and clinical features. Ann Oncol 25 (2014), 1995–2001.
29. 29 Torti, D, Trusolino, L, Oncogene addiction as a foundational rationale for targeted anti-cancer therapy: promises and perils. EMBO Mol Med 3 (2011), 623–636.
30. 30 Scaltriti, M, Nuciforo, P, Bradbury, I, et al. High HER2 expression correlates with response to the combination of lapatinib and trastuzumab. Clin Cancer Res 21 (2015), 569–576.
31. 31 Montemurro, F, Scaltriti, M, Biomarkers of drugs targeting HER-family signalling in cancer. J Pathol 232 (2014), 219–229.
32. 32 Bang, YJ, Van Cutsem, E, Feyereislova, A, et al. Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial. Lancet 376 (2010), 687–697.
33. 33 Shaw, AT, Kim, DW, Nakagawa, K, et al. Crizotinib versus chemotherapy in advanced ALK-positive lung cancer. N Engl J Med 368 (2013), 2385–2394.